Dermatologic Therapy最新文献

{"title":"Treatment Resistance to TNF-α Inhibitors in Patients with Psoriasis","authors":"Amirmansoor Gholami,&nbsp;Ahmad Vafaeian,&nbsp;Maryam Daneshpazhooh,&nbsp;Ifa Etesami,&nbsp;Kamran Balighi,&nbsp;Delnavaz Jan,&nbsp;Ali Salehi Farid,&nbsp;Ali Vafaei,&nbsp;Hamidreza Mahmoudi","doi":"10.1155/2023/7399468","DOIUrl":"10.1155/2023/7399468","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Treatment resistance to biologic treatment at specific sites in the body is a challenging issue. However, there is insufficient evidence for factors affecting the resistance of these areas to biological therapies. <i>Methods</i>. In this study, patients with moderate-to-severetreatment-resistant psoriasis who were biologic naïve and referred to Razi hospital were included. The relationship between treatment resistance in different areas and demographic and clinical variables was investigated. <i>Results</i>. A total of 131 biologic-naïve patients with psoriasis treated with anti-TNF-<i>α</i> were included in this study. The most common resistant sites included the scalp, anterior lower legs, and elbows. Also, hand- and toe-nail involvements were considerable. BMI, gender, smoking, PASI score, the duration of the disease, the time distance between diagnosis and treatment, and treatment regiments were found to affect the incidence of resistance to treatment in multiple areas, while age, the incidence of recalcitrant disease and/or psoriatic arthritis, and the duration of current treatment did not have effects. <i>Conclusion</i>. The most common refractory sites were the scalp, anterior lower legs, and elbows. This study should be followed up with larger samples containing a variety of biological treatments in order to evaluate the results.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/7399468","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138949977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous T-Cell Lymphoma","authors":"David M. Weiner,&nbsp;Supriya Rastogi,&nbsp;Daniel J. Lewis,&nbsp;Leah Cohen,&nbsp;Sara Choi,&nbsp;Carmela C. Vittorio,&nbsp;Paul L. Haun,&nbsp;Sara S. Samimi,&nbsp;Jennifer Villasenor-Park,&nbsp;Rahul S. Bhansali,&nbsp;Elise A. Chong,&nbsp;Daniel J. Landsburg,&nbsp;Sunita D. Nasta,&nbsp;Stephen J. Schuster,&nbsp;Jakub Svoboda,&nbsp;Ellen J. Kim,&nbsp;Alain H. Rook,&nbsp;Stefan K. Barta","doi":"10.1155/2023/7625926","DOIUrl":"10.1155/2023/7625926","url":null,"abstract":"<div>\u0000 <p>Mogamulizumab is a novel monoclonal antibody designed to target CC chemokine receptor 4 (CCR4), which is expressed by tumor cells in cutaneous T-cell lymphoma (CTCL). In clinical trials, mogamulizumab monotherapy has demonstrated efficacy in reducing tumor burden in advanced CTCL, particularly in the peripheral blood. In clinical practice at our center, mogamulizumab has been combined with other agents such as systemic interferon, systemic retinoids, and extracorporeal photopheresis for an enhanced synergistic effect. There is limited published research on mogamulizumab combination therapy. This study evaluates the clinical efficacy of mogamulizumab in combination with systemic interferon, retinoids, and/or extracorporeal photopheresis for therapy of CTCL. Nineteen patients on this regimen at our academic center were identified. Treatment response rates, progression-free survival, duration of response, and adverse effects were characterized by retrospective chart review. All patients on this regimen at our center had an initial partial or complete response. Moreover, responses were durable, and the regimen was well-tolerated with few grade 3 adverse effects. These results demonstrate the utility of a multimodality approach to the therapy of CTCL with mogamulizumab and warrant further confirmation.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/7625926","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138959724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gasdermin C (GSDMC) is Overexpressed in Psoriatic Tissue and Elevated in Psoriatic Serum: A Potential Marker of Cell Proliferation and Local Hypoxia in Psoriasis?","authors":"Julia Nowowiejska,&nbsp;Anna Baran,&nbsp;Justyna Magdalena Hermanowicz,&nbsp;Anna Pryczynicz,&nbsp;Beata Sieklucka,&nbsp;Dariusz Pawlak,&nbsp;Iwona Flisiak","doi":"10.1155/2023/7813287","DOIUrl":"10.1155/2023/7813287","url":null,"abstract":"<div>\u0000 <p>Psoriasis is an important disease in dermatological practice and, despite many studies, its pathogenesis is still not fully understood. Gasdermin C (GSDMC; melanoma-derived leucine zipper-containing extranuclear factor, MLZE) is a member of the gasdermin protein family. The study enrolled 60 patients with active plaque-type psoriasis and 30 volunteers without dermatoses. GSDMC concentration was assessed in serum and urine samples of all participants using ELISA. GSDMC tissue expression was assessed by immunohistochemistry. The GSDMC concentration was significantly higher in serum of patients than in controls (<i>p</i> &lt; 0.001). A urinary GSDMC/creatinine ratio was significantly lower in patients than in controls (<i>p</i> &lt; 0.05). Psoriatic lesions exhibited a significantly higher expression of GSDMC than nonlesional patients’ skin or controls’ skin (<i>p</i> &lt; 0.001, <i>p</i> &lt; 0.01, respectively). There was a positive correlation between the GSDMC serum concentration and the age of patients (<i>R</i> = 0.31, <i>p</i> = 0.015) and a negative correlation between GSDMC and RBC (<i>R</i> = −0.37; <i>p</i> = 0.0038), HGB (<i>R</i> = −0.26; <i>p</i> = 0.047), and urea concentration (<i>R</i> = −0.36; <i>p</i> = 0.04). Our study shows the potential involvement of GSDMC in psoriasis. An increased serum GSDMC and a decreased urinary GSDMC/creatinine ratio could be considered noninvasive psoriasis biomarkers, especially of local hypoxia or cell proliferation.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/7813287","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138966860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unique Retinol Therapy with Antioxidant and Anti-Inflammaging Complex for Naturally Reborn Skin: The Clinical Case Series Study","authors":"D. Sołdacka,&nbsp;M. Podgórska,&nbsp;W. Barańska-Rybak","doi":"10.1155/2023/5588525","DOIUrl":"10.1155/2023/5588525","url":null,"abstract":"<div>\u0000 <p>One of the methods used to prevent symptoms of skin aging are chemical peels. Among retinoids, retinol is much less described in the literature than tretinoin as a substance used in the peel procedure. The aim of our study was to determine the efficacy of using a 4% retinol solution product containing novel TGF-<i>β</i> activators and antioxidants in improving the condition of the skin in patients with facial skin issues caused by aging and skin disorders. Each of 15 patients went through three peel treatment series, with a 30-day gap between each session and was examined using Multi Skin Test MC 1000 Courage + Khazaka, evaluating hydration, elasticity, and skin pigmentation and Observ 520x. All patients reported overall improvement after the peeling procedure, and most of them reported subjective improvement in the reduction of the facial skin: tone, skin pigmentation, dehydration, dryness, structure, and sebaceous gland activity. An objective evaluation revealed significant clinical improvement in pigmentation in study groups. Elasticity parameters were shown to increase during treatment, with a greater effect occurring in patients with mature skin with first signs of aging and patients with postinflammatory hyperpigmentation, atrophic acne scars, and enlarged pores. Concluding, combined peel therapy of 4% retinol serum product containing novel TGF-<i>β</i> activators and antioxidants showed good efficacy in reducing facial pigmentation of the skin high patients’ satisfaction with the procedure. The study revealed that the described method is simple to use, has low cost, is with rare adverse events, and has well tolerability.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/5588525","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138594180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Cryotherapy and Topical Salicylic Acid in Common Warts: A Systematic Review and Meta-Analysis","authors":"Dipika Chaudhary,&nbsp;Yan Sun,&nbsp;Xinghua Gao","doi":"10.1155/2023/4283918","DOIUrl":"10.1155/2023/4283918","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Common warts are most common complaint among children and adults caused by human papillomavirus (HPV). Cryotherapy and topical salicylic acid are common therapies. <i>Objective</i>. To compare the efficacy and safety of cryotherapy and topical salicylic acid in common warts. <i>Methods</i>. Randomized controlled trials (RCTs) comparing cryotherapy and topical salicylic acid treatment in patients with common warts were searched by using PubMed, Embase, Google Scholar, and Cochrane Database of Systematic Reviews up to Oct 20, 2021. The keywords were “common warts/verruca,” “cryotherapy,” and “salicylic acid.” The language was restrained to English. No age or gender limitation was conducted. The outcomes were complete remission of all warts at different observation times, recurrence rates, and side effects. Study-specific effect sizes were pooled by using the fixed-effects model and the Mantel–Haenszel method. <i>I</i>² was used to assess heterogeneity of studies. <i>Results</i>. Seven articles involving 976 patients randomized into the cryotherapy group or salicylic acid group were included. Of whom, 487 patients received cryotherapy, while 489 received salicylic acid treatment. With the fixed-effects model, the pool effect of complete clearance of warts at 12 weeks comparing cryotherapy and salicylic acid was not statistically significant (RR = 0.99 (0.84–1.17), <i>I</i>² = 0%). <i>Conclusion</i>. Comparable efficacy of cryotherapy and topical salicylic acid was conducted in common wart treatment. More high-quality pieces of evidence with more samples are needed to confirm the results for further recommendations.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/4283918","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139232681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of 730 nm Picosecond Laser for the Treatment of Freckles and Solar Lentigines: A Retrospective Analysis","authors":"Qilei Che,&nbsp;Qingbiao Wa,&nbsp;Lufeng Liu,&nbsp;Qiuyue Tang,&nbsp;Yulian Gao,&nbsp;Jie Lu,&nbsp;Zixuan Zhou,&nbsp;Yuhong Xie","doi":"10.1155/2023/2070560","DOIUrl":"10.1155/2023/2070560","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Freckles and solar lentigines are epidermal pigmentation disorders that affect the face and impact the quality of life of affected individuals. <i>Aims</i>. We aimed to observe and evaluate the clinical effectiveness of a 730 nm picosecond laser for the treatment of freckles and solar lentigines. <i>Methods</i>. We retrospectively collected patient information on freckles and solar lentigines and observed and evaluated the clinical outcome of a 730 nm picosecond laser. These included lesion clearance and recurrence rates, adverse reactions, and patient satisfaction. <i>Results</i>. Fifty cases of freckles and solar lentigines reported between January 1, 2022, and July 1, 2022, were included. All patients received two 730 nm picosecond laser treatments. The lesion clearance rates after one and two treatments were 53.1% and 78.4%, respectively, and the rates after one and six months of treatment were 78.7% and 78.4%, respectively. 90% of the patients reported ≥95% clearance of lesions after six months via a questionnaire survey. Among the patients, 86.0% were satisfied with their treatment. Postinflammatory hyperpigmentation occurred in two patients, both of whom had Fitzpatrick skin type IV. There was no recurrence of lesions. <i>Conclusions</i>. The 730 nm picosecond laser treatment for freckles and solar lentigines has the advantages of a high clearance rate, low recurrence rate, and high patient satisfaction. This trial is registered with ChiCTR2200058573.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/2070560","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139245631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mask-Acne Prevalence and Risk Factors during the COVID-19 Pandemic: A Cross-Sectional Single Institution Study","authors":"Ahmad Berjawi,&nbsp;Pascale Salameh,&nbsp;Naya Fadel,&nbsp;Jinane R. El Khoury","doi":"10.1155/2023/9470636","DOIUrl":"10.1155/2023/9470636","url":null,"abstract":"<div>\u0000 <p>Mask usage in healthcare workers became a requirement in all hospitals after the COVID-19 pandemic. Dermatologists have increasingly been diagnosing facial skin reactions that were attributed to or exacerbated by increased mask usage. “Mask-acne,” which is defined as a new onset or exacerbation of acne localized to the facial area under the mask, has been increasingly reported in the general population and healthcare workers during the COVID-19 pandemic. The purpose of this study is to assess the prevalence, severity, and risk factors contributing to mask-acne development among healthcare workers at a tertiary care center. The study was carried out via a web-based questionnaire. We evaluated healthcare workers’ demographics, mask behaviors, confounding factors, and prevalence of mask-acne. The total number of responders was 201, most responders were physicians (62.7%), and the surgical mask was the most used type of mask (62.1%). Results showed that 40.2% of healthcare workers developed mask-acne with 62.9% of them having new onset mask-acne and 37.1% having an exacerbation of preexisting acne. Age &lt;30 years, female gender, and prolonged mask usage &gt;8 hours were significantly associated with mask-acne development. The study highlights the prevalence of mask-acne among HCWs and risk factors that contribute to its development in the hospital setting.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/9470636","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139251445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intradermal Local Injection of Autologous Cell-Free Fat Extract for the Treatment of Refractory Postinflammatory Hyperpigmentation","authors":"Yizuo Cai,&nbsp;Zhuoxuan Jia,&nbsp;Jiancheng Gu,&nbsp;Bijun Kang,&nbsp;Hongjie Zheng,&nbsp;Wei Li,&nbsp;Wenjie Zhang","doi":"10.1155/2023/9561809","DOIUrl":"10.1155/2023/9561809","url":null,"abstract":"<div>\u0000 <p>Current treatment modalities for postinflammatory hyperpigmentation (PIH) often fall short in delivering satisfactory results for some patients. Therefore, this study aimed to assess the efficacy and tolerability of autologous cell-free fat extract (CEFFE) in the treatment of PIH. We enrolled 15 patients with PIH and administered them with five intracutaneous CEFFE injections, each at a two-week interval. Evaluation included efficacy assessment using objective (standard two-dimensional photos, VISIA®-photos, brown spot (BS) index, lesion lightness, lesion color, and trans-epidermal water loss) and subjective (Global Aesthetic Improvement Scale and Likert satisfaction scale) parameters and tolerance assessment. Following CEFFE treatment, significant reductions were observed in the BS index (<i>p</i> &lt; 0.05) and transepidermal water loss (<i>p</i> &lt; 0.05), while skin lightness and lesion color showed significant improvements (<i>p</i> &lt; 0.05) at the 12-month follow-up. Subjectively, 93.33% of patients reported improved or greatly improved conditions after 12 months of treatment. Transient local bruising and stinging were the only observed treatment-related adverse events, with no serious complications reported. These findings demonstrate that intradermal injections of CEFFE are well-tolerated and effective for the treatment of PIH. This trial is registered with ChiCTR2000039381.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/9561809","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139263942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Topical Scalp Serum Containing Adenosine, MgSO4, Vitamin CG, and Pre- and Probiotic Fractions Reduces Discomfort and Associated Symptoms of Sensitive Scalp","authors":"Philippe Massiot,&nbsp;Françoise Magne,&nbsp;Florence Weisgerber,&nbsp;Anais Thomet,&nbsp;Florence Pouradier,&nbsp;Geneviève Loussouarn,&nbsp;Delphine Kerob","doi":"10.1155/2023/7225231","DOIUrl":"10.1155/2023/7225231","url":null,"abstract":"<div>\u0000 <p><i>Purpose</i>. Sensitive scalp (SScalp) is characterized by abnormal and nociceptive sensations, such as stinging and itching, that lead to scalp discomfort. This study assessed the benefit of a once-daily serum containing Adenosine, Magnesium Sulfate (MgSO₄₎, Vitamin C Glucoside (CG), and pre- and probiotic fractions in subjects with SScalp. <i>Methods</i>. An open-label, single center study in adult subjects with a Global Scalp Discomfort (GSD) score of ≥8 (0–27), defined as the sum of individual symptom scores (0–9) for itching, stinging, and warming sensations. The frequency of scratching was self-declared. Evaluations were performed immediately after the 1^st application (D0Timm) and at D21, during which the cosmetic acceptability was additionally assessed. Transepidermal water loss and skin hydration were assessed at baseline, D21, and D28. Squalene (SQ) and SQOOH were analyzed at D0T0, D21T0, and D28. Tolerance was assessed throughout the study. <i>Results</i>. 42 subjects (30 women and 12 men) participated in this study. The mean age was 44.0 ± 13.0 years. At baseline, the mean GSD was 13.9 ± 3.28. The GSD and symptoms significantly (<i>p</i>  &lt;  0.0001) improved at D0Timm and lasted until the end of the study (D28), with insignificant worsening. There was a significant reduction of SQOOH at D21 and D28. Subject satisfaction was high, associated with a good tolerance. A similar and significant (<i>p</i>  &lt;  0.0001) improvement was observed for subjects with more severe symptoms and a GSD score ≥14 at baseline. <i>Conclusion</i>. The topical serum significantly reduces SScalp, global discomfort, and oxidative stress and is beneficial in the management of sensitive scalp. This TRIAL is registered with NCT05630027.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/7225231","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136351629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Schizophrenia in Patients with Psoriasis: A Systematic Review and Meta-Analysis","authors":"Peixin Zhu,&nbsp;Qi He,&nbsp;Xiyan Liu,&nbsp;Chunyue Huo","doi":"10.1155/2023/6624793","DOIUrl":"10.1155/2023/6624793","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Several studies have shown that psoriasis patients have a higher prevalence rate of schizophrenia, but none has thoroughly examined this association across different ages and genders. Thus, our systematic review and meta-analysis aims to combine all available evidence and evaluate the risk of schizophrenia in psoriasis patients. <i>Methods</i>. Two independent investigators extracted published studies from PubMed, Embase, Medline, and Web of Science databases from inception until May 2023 and screened 160 articles for eligibility. We included 8 studies in this meta-analysis. A random-effects model was employed to estimate the pooled odds ratio (OR) and 95% confidence interval (CI) for schizophrenia in patients with psoriasis. The study protocol is registered with PROSPERO, number CRD42023428576. <i>Results</i>. A total of eight studies with 889,747,79 participants met the eligibility criteria. The pooled OR of psoriasis in patients with schizophrenia versus subjects without schizophrenia was 1.66 (95% CI: [1.20, 2.29]) with a significant level of heterogeneity (<i>I</i>² = 97%). Specifically, the OR for psoriasis in children with schizophrenia was 12.90 (95% CI: [1.97, 84.64]), with an <i>I</i>² combined value of 98% and psoriasis in adults with schizophrenia 2.57 (95% CI: [1.44, 4.58]), with an <i>I</i>² combined value of 61.3%. The combined OR for all age groups was 5.27 (95% CI: [3.02, 9.19]). Additionally, we found that the OR value for psoriasis in females with schizophrenia was 1.74 (95% CI: [1.74, 2.11]), with an <i>I</i>² combined value of 59%. For male patients, the OR value was 1.58 (95% CI: [1.25, 2.01]), with an <i>I</i>² combined value of 77%. <i>Conclusions</i>. Our study shows an increased risk of schizophrenia in people with psoriasis. We demonstrated a significantly increased risk of schizophrenia among children with psoriasis and found that females with psoriasis were more likely to have schizophrenia than men with psoriasis under the same conditions.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2023 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/6624793","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135041979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}